Page 8 - Partial Response News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Preliminary Data for SRF617 Show Good Tolerability and Promise in Combination Approaches Company to Hold Webcast to Review Data from Ongoing SRF388 and SRF617 Phase 1 Clinical Studies on Friday, June 4th at 8:00 a.m. ET CAMBRIDGE, Mass., June 04, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new data from the ongoing Phase 1 s

California’s new attorney general has vowed to focus on hate crimes in response to the spate of anti-Asian incidents recorded in the state. Rob Bonta, who is Filipino American, detailed his plan on Tuesday in his first press conference since he was sworn in to replace Xavier Becerra last month. A new bureau: Bonta is creating a new Racial Justice Bureau within his California Department of Justice to deal with hate crimes.

Theralase Technologies Inc.: Theralase Releases Quarterly Newsletter ® Technologies Inc. (" TSXV:TLT)( OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (" PDC") and associated drug formulations to safely and effectively destroy various cancers, bacteria and viruses has released the Company's Quarterly Newsletter (" Newsletter") which provides updates on the previous quarter and progress on the Phase II Non-Muscle Invasive Bladder Cancer (" NMIBC") Clinical Study (" Highlights from the Newsletter: Clinic...

Share this article Share this article BOTHELL, Wash., April 13, 2021 /PRNewswire/ -- Qilu Puget Sound Biotherapeutic Corp. (Sound Biologics), an emerging biotechnology company focused on developing a novel MabPair ™ platform for antibody-based combination therapies for the treatment of cancer, inflammation and autoimmune disease, announced a clinical update on its first MabPair product PSB205 at the American Association for Cancer Research (AACR) Annual Meeting. Dr Li Zhang of Sun Yat-Sen University Cancer Centre (SYSUCC), Guangzhou, China presented a poster on Phase 1 Clinical Trial result...

News Category Global Banking & Finance Reviews NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer NuCana Presents Encouraging Data at ASCO GI for NUC-3373 in Heavily Pre-Treated Patients with Metastatic Colorectal Cancer Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be Favorable EDINBURGH, United Kingdom, Jan. 15, 2021 — NuCana plc (NASDAQ: NCNA) today announced interim data from the ongo...